[ad_1]
Toronto and Herzliya, Israel, July 10, 2021 (Global News Agency) – InterCure Co., Ltd.. (Toronto Stock Exchange:Increment, TASE: INCR))(dba Canndoc)(“the company“) is pleased to announce that it is reporting to the U.S. Securities and Exchange Commission (“Securities and Exchange Commission“)’S 20F registration statement on April 20, 2021, and it will publicly submit its 20F registration statement in the week of July 11. The company also applies for the listing of its common stock (“Common stock“) On the Nasdaq Capital Market (“Nasdaq“), the transaction code is “INCR”, waiting for the public submission of the 20F registration statement and meeting certain other conditions. The company expects that common shares will begin trading on the Nasdaq in the last week of July 2021.
The company believes that the NASDAQ listing will enable the company to expand its global exposure and enhance shareholder value through the world’s largest capital market. The company believes that this listing will provide existing investors with additional liquidity and provide potential investors with better opportunities…
The full story on Benzinga.com
[ad_2]
Source link
